Growth Drivers

Lead Asset PMN310 Progressing in Alzheimer’s Disease: PMN310, a humanized monoclonal antibody targeting toxic amyloid-beta oligomers, is advancing through a Phase 1b clinical trial with over 85% enrollment and no observed amyloid-related imaging abnormalities (ARIA) to date. The favorable safety profile and Fast Track designation from the FDA position PMN310 as a differentiated candidate in a high-unmet-need market, with interim and top-line data expected in 2026. Success could drive significant long-term revenue growth if efficacy is demonstrated and regulatory milestones are achieved.

Proprietary EpiSelect™ Platform for Pipeline Expansion: The EpiSelect™ computational platform enables the identification of disease-specific epitopes on misfolded proteins, supporting a pipeline beyond Alzheimer’s disease, including programs in ALS and Parkinson’s disease. This platform approach offers scalability and the potential for multiple shots on goal, enhancing long-term growth prospects if additional candidates advance to clinical development.

Strategic Board Strengthening and Capital Market Access: The appointment of Dr. Slanix Paul Alex, an experienced healthcare investor, to the Board and ongoing support from Ally Bridge Group improve ProMIS’s access to capital and strategic guidance. This strengthens the company’s ability to fund development and navigate the competitive biotech landscape over the next decade.

ProMIS Neurosciences’ growth is anchored by the clinical advancement of PMN310 in Alzheimer’s disease, a scalable antibody discovery platform, and improved capital market access. These drivers provide a credible path to long-term value creation, contingent on clinical and regulatory success.

Growth Limitations

Single-Asset Clinical and Regulatory Risk: The company’s near-term value is heavily dependent on the success of PMN310, which remains in early-stage clinical development. Failure to demonstrate efficacy or safety in upcoming trials would severely limit revenue and valuation growth over the next 10 years.

Limited Financial Resources and Ongoing Losses: ProMIS reported $15.4 million in cash as of September 2025, with quarterly operating losses of $11.8 million driven by R&D expenses. Without near-term revenue, the company is reliant on external financing, which may be dilutive or unavailable if clinical results disappoint.

Nasdaq Compliance and Reverse Stock Split: The need for a 1-for-25 reverse stock split to regain Nasdaq compliance highlights persistent share price weakness and potential investor skepticism. Ongoing listing risk could impact liquidity, access to capital, and investor confidence.

ProMIS faces high structural risk from its single-asset focus, limited cash runway, and ongoing listing compliance challenges. These factors could cap long-term growth if not addressed through successful clinical outcomes and capital raising.

Scalable Growth Initiatives

Advancement of PMN310 in Alzheimer’s Disease: The PRECISE-AD Phase 1b trial is designed to generate safety and biomarker data to support further development. If successful, this could enable pivotal trials and potential partnerships, unlocking significant upside.

Pipeline Expansion into ALS and Parkinson’s Disease: Programs PMN267 (ALS) and PMN442 (Parkinson’s/MSA) are ready for IND-enabling studies. Progression of these assets could diversify risk and create new growth avenues if clinical milestones are met.

Leveraging EpiSelect™ Platform for New Indications: The EpiSelect™ platform’s ability to generate selective antibodies against misfolded proteins positions ProMIS to pursue additional neurodegenerative targets, supporting long-term pipeline scalability.

ProMIS’s scalable growth initiatives center on advancing PMN310, expanding its pipeline, and leveraging its proprietary platform. Execution on these fronts could transform the company’s growth profile, but success is highly execution- and data-dependent.

Structural Risk Factors

Clinical Development and Regulatory Uncertainty: As a clinical-stage biotech, ProMIS faces high risk of trial failure, regulatory setbacks, or delays, any of which could materially erode its position and future cash flows.

Competitive Alzheimer’s Disease Landscape: The Alzheimer’s market is crowded with large-cap competitors and multiple late-stage programs. Even with a differentiated mechanism, ProMIS must demonstrate clear clinical benefit and safety to secure market share.

Sustained Capital Needs and Dilution Risk: Ongoing R&D and operating losses require repeated capital raises, which may be dilutive to existing shareholders, especially if market sentiment weakens or clinical data disappoints.

ProMIS is exposed to high structural risk from clinical, regulatory, and financial uncertainties, as well as intense competition. These risks could disrupt or erode its position over the next decade if not mitigated by successful execution.

Overall Score

ProMIS Neurosciences offers moderate 10-year growth potential, underpinned by a promising lead asset and scalable platform, but faces high risk from clinical, financial, and competitive pressures. Long-term value creation is contingent on successful clinical outcomes, capital access, and pipeline execution.